血小板与淋巴细胞比值对喉癌复发的预测价值

doi:10.6040/j.issn.1673-3770.1.2019.018

摘要/Abstract

摘要： 目的

探讨术前外周血血小板与淋巴细胞比值(PLR)、中性粒细胞与淋巴细胞比值（NLR）、衍生中性粒细胞与淋巴细胞比值（dNLR）对喉鳞状细胞癌患者复发的影响和预测价值。

方法

回顾性分析南京医科大学第一附属医院473例行初次手术治疗的喉鳞状细胞癌患者的临床资料。根据患者术前的PLR、NLR和dNLR，绘制诊断肿瘤复发的受试者工作特征曲线（ROC），确定PLR、NLR和dNLR界值，从而分成相应的低比值组和高比值组；并采用 Kaplan-Meier分析、COX风险模型分析PLR、NLR、dNLR以及其他临床病理参数与喉癌复发的关系。

结果

PLR、NLR和dNLR诊断肿瘤复发的ROC曲线下面积(AUC)分别为0.683、0.720和0.696。单因素分析显示: PLR、NLR、dNLR、分型、分期、病理分化程度、甲状软骨板累及、淋巴结转移、年龄、凝血功能与喉鳞状细胞癌患者的复发有关；COX风险模型显示: PLR、分型、年龄是影响喉鳞状细胞癌复发的独立危险因素。

结论

术前PLR高的喉鳞状细胞癌患者术后容易复发，PLR对复发的预测价值优于NLR和dNLR，可作为评估喉癌患者预后的重要指标。

关键词: 喉肿瘤，鳞状细胞, 血小板与淋巴细胞比值, 中性粒细胞与淋巴细胞比值, 复发, 预后

Abstract: Objective

To evaluate the impact of preoperative platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR) and derived NLR (dNLR) on the prognosis in patients with laryngeal squamous cell carcinoma.

Methods

The clinical data of 473 patients with laryngeal squamous cell carcinoma who underwent primary surgery in the First Affiliated Hospital of Nanjing Medical University were analyzed retrospectively. According to preoperative PLR, NLR and dNLR, the receiver operating characteristic curve (ROC) for diagnosing tumor recurrence was drawn to determine PLR, NLR and dNLR thresholds, and then the patients were divided into the lower groups and the higher groups. Kaplan-Meier analysis and COX risk model were used to analyze the relationship between PLR, NLR, dNLR, and other clinicopathological parameters and recurrence of laryngeal squamous cell carcinoma.

Results

The area under the ROC curve (AUC) of PLR, NLR and dNLR for the diagnosis of tumor recurrence were 0.683, 0.720 and 0.696, respectively. Univariate analysis showed that PLR, NLR, dNLR, tumor classification, TNM stages, pathological differentiation, invasion of thyroid cartilage plate, lymph nodes metastasis, age and coagulation were associated with recurrence in patients with laryngeal squamous cell carcinoma; In COX regression model, a higher PLR, tumor classification and age were identified as independent risk factors for the recurrence of laryngeal squamous cell carcinoma (P<0.001; P=0.033; P=0.030).

Conclusion

Laryngeal squamous cell carcinoma patients with high preoperative dNLR are more likely to relapse. Preoperative PLR is a more valuable prognostic factor than NLR and dNLR for recurrence of laryngeal squamous cell carcinoma. It could be a clinically biomarker for the prognosis of laryngeal squamous cell carcinoma.

Key words: Laryngeal neoplasms, squamous cell, Platelet-lymphocyte ratio, Neutrophil-lymphocyte ratio, Recurrence, Prognosis

中图分类号:

R767

陈慧君,宋圣花,周涵,董伟达,乔明哲,陈曦,徐进,林子萍,邢光前. 血小板与淋巴细胞比值对喉癌复发的预测价值[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 106-110.

Huijun CHEN,Shenghua SONG,Han ZHOU,Weida DONG,Mingzhe QIAO,Xi CHEN,Jin XU,Ziping LIN,Guangqian XING. Preoperative platelet-lymphocyte ratio is an independent prognostic factor for laryngeal squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 106-110.

图/表 6

图1

图 2

图3

图4

表1

Kaplan-Meier生存分析：以喉癌复发为终点，研究不同组之间的差异"

变量

平均值（月）

CI（月）

3年生存率（%）

χ 2

dNLR

低

高

93.988

67.571

90.167~97.810

60.724~74.419

78.164

59.864

49.165

<0.001

NLR

低

高

96.185

72.316

92.107~100.262

66.675~77.958

78.039

64.762

43.232

<0.001

PLR

低

高

94.284

72.035

90.176~98.392

66.185~77.885

75.800

66.304

39.036

<0.001

分型

非声门型

声门型

67.656

90.374

59.090~76.222

86.639~94.109

54.286

75.543

28.447

<0.001

分期

I+II

III+IV

90.823

70.084

87.098~94.549

62.052~78.116

77.778

52.672

26.108

<0.001

病理分化

低分化

中+高分化

64.908

87.606

52.291~77.525

83.940~91.272

47.541

74.272

14.723

<0.001

甲状软骨板累及

无

有

86.757

65.196

83.144~90.371

48.735~81.656

72.789

43.750

11.992

0.001

淋巴结转移

无

有

88.984

61.431

85.359~92.609

50.596~72.266

74.631

47.761

28.793

<0.001

年龄

＜60岁

≥60岁

90.846

81.306

85.451~96.242

76.620~85.991

77.325

67.110

6.256

0.012

凝血功能

正常

异常

88.411

74.446

84.610~92.212

65.512~83.379

77.839

51.430

11.685

0.001

表1

表 2

参考文献 14

1	黄选兆, 汪吉宝, 孔维佳. 实用耳鼻咽喉头颈外科学[M]. 北京: 人民卫生出版社，2008:488.
2	FengJF, HuangY, ChenQX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma[J]. World J Surg Oncol, 2014, 12: 58. doi:10.1186/1477-7819-12-58. doi: 10.1186/1477-7819-12-58
3	IshizukaM, NagataH, TakagiK, et al. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer[J]. Br J Cancer, 2013, 109(2): 401-407. doi:10.1038/bjc.2013.350. doi: 10.1038/bjc.2013.350
4	RussoA, FranchinaT, RicciardiGRR, et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel[J]. J Cell Physiol, 2018, 233(10): 6337-6343. doi:10.1002/jcp.26609. doi: 10.1002/jcp.26609
5	KangMY, JeongCW, KwakC, et al. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor[J]. Oncotarget, 2017, 8(8): 12891-12901. doi:10. 18632/oncotarget.14179. doi: 10. 18632/oncotarget.14179
6	SabrkhanyS, GriffioenAW, Oude EgbrinkMG. The role of blood platelets in tumor angiogenesis[J]. Biochim Biophys Acta, 2011, 1815(2): 189-196. doi:10.1016/j.bbcan. 2010.12.001. doi: 10.1016/j.bbcan. 2010.12.001
7	MantovaniA, AllavenaP, SicaA, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444. doi:10.1038/nature07205. doi: 10.1038/nature07205
8	GrenaderT, NashS, PlotkinY, et al. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies[J]. Ann Oncol, 2015, 26(9): 1910-1916. doi:10.1093/annonc/mdv253. doi: 10.1093/annonc/mdv253
9	KucharczykJ, SullivanC, LuJ, et al. Prognostic and predictive value of pretreatment derived neutrophil-to-lymphocyte ratio in non-small-cell lung cancer patients treated with an immune checkpoint inhibitor[J]. JCT, 2018, 9(1): 23-34. doi:10.4236/jct.2018.91004. doi: 10.4236/jct.2018.91004
10	DiricanA, KucukzeybekBB, AlacaciogluA, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?[J]. Int J Clin Oncol, 2015, 20(1): 70-81. doi:10.1007/s10147-014-0672-8. doi: 10.1007/s10147-014-0672-8
11	EthierJL, DesautelsD, TempletonA, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis[J]. Breast Cancer Res, 2017, 19(1): 2. doi:10.1186/s13058-016-0794-1. doi: 10.1186/s13058-016-0794-1
12	ChenL, ZhangF, ShengXG, et al. Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: lymphocyte[J]. Medicine (Baltimore), 2016, 95(32): e4381. doi:10.1097/MD. 000-0000000004381. doi: 10.1097/MD. 000-0000000004381
13	JainS, HarrisJ, WareJ. Platelets: linking hemostasis and cancer[J]. Arterioscler Thromb Vasc Biol, 2010, 30(12): 2362-2367. doi:10.1161/ATVBAHA.110.207514. doi: 10.1161/ATVBAHA.110.207514
14	SuzukiK, AiuraK, UedaM, et al. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents[J]. Pancreas, 2004, 29(2): 132-140.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

变量	HR	HR（CI）	B	P
分型	0.640	0.424~0.964	-0.447	0.033
PLR	2.011	1.378~2.936	0.699	＜0.001
年龄	1.537	1.043~2.265	0.430	0.030

[1]	潘晓菲,王军,肖洋,马丽晶. LncRNA CTB-147C22.8对复发性呼吸道乳头状瘤细胞侵袭的影响[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 66-70.
[2]	黄河,欧阳晖. 下咽癌共病食管癌的高危因素及预后分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 82-86.
[3]	赵青,周涵,殷敏,冯剑,张佳程,刘雅琴,沈宇杰,林子萍,董伟达. 鼻咽纤维血管瘤术前超选择性血管栓塞的应用价值[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 100-105.
[4]	张佳程,张立庆,周涵,陆美萍,许万云,沈宇杰,刘雅琴,殷敏,董伟达. 鼻腔鼻窦恶性黑色素瘤23例临床分析[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 95-99.
[5]	姜彦. 鼻咽癌复发及鼻内镜外科手术的应用[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 1-11.
[6]	陈冬平,杨致欢,张炎,方楠,齐斌. 复发鼻咽癌手术治疗地位的思考[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 12-16.
[7]	徐文瑞,姜彦. 复发鼻咽癌挽救性手术方法研究进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 35-38.
[8]	刘传合. 我国儿童哮喘患病与诊治现状[J]. 山东大学耳鼻喉眼学报, 2019, 33(1): 28-32.
[9]	雷文斌,刘其洪. CO₂激光手术治疗复发性呼吸道乳头状瘤[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 8-12.
[10]	刘晓静,王愿,张立庆,冯剑,赵青,宋圣花,周涵,董伟达. 鼻窦骨纤维异常增殖症36例临床分析[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 73-78.
[11]	吕丹,李明霞,马兰枝,张馨元,肖浩,陈飞,刘均,李珍. 累及纵膈的头颈部丛状I型神经纤维瘤病两例[J]. 山东大学耳鼻喉眼学报, 2018, 32(1): 82-86.
[12]	伦杰,张亚楠. 慢性鼻-鼻窦炎伴鼻息肉复发的相关影响因素分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 80-83.
[13]	包伟晶,宁佳羽,朱忠寿,魏日富,林昶. CO₂激光切除累及前联合的早期声门癌26例[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 101-105.
[14]	贾岩峰,杨春伟,宋富春,杨相立,王林,刘吉祥. CO₂激光联合质子泵抑制剂治疗复发性声带突肉芽肿的疗效观察[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 106-109.
[15]	马荣峰,朱富高,孙美红,付涛,张晓恒,曹琳. 突发性聋预后的相关因素分析及疗程选择[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 69-74.